As of today, what is the value and feasibility of implementing each DCT solution?



Should decentralized elements be mandatory in all trials?



Closing poll: Reflecting on these challenges, what solutions or next steps are most important to consider?

EDUCATION, EDUCATION, EDUCATION on DCTs.

continue knowledge sharing and education on topics related to decentralized clinical trial solutions

Rebuilding trust by patients and their carers,families in research community, industry, and the healthcare system.

Education for sites & patients. We need to support their understanding of what DCTs means for them, wants in for them.

continue to work cross collaboratively to work through the challenges

Share what was learned/identified in this conference with broader audience. Keep dialog open.

Further collaboration across interest groups whether it be through forums like this, roundtable discussions, etc.

Alignment on regulations and stakeholder education and training

shape regulatory landscape to enable DCTs more broadly

Closing poll: Reflecting on these challenges, what solutions or next steps are most important to consider?

CTTI can work to make the regulatory environment more uniform across jurisdictions.

harmonization of regulation guidance

Promoting more collaboration with all stakeholders (regulatory agencies, industry, clinics & trial participants)

Coming up with a consolidated approach to address these challenges similar to Transcelerate - i.e. single protocol designs they have done. In using a similar approach with DCT, I think the challenges will be easier to address.

1) Harmonization of regulations globally. 2) Terminology unification with training and education. 3) Operationalizing DCT. 4) Technology adoption, access, integration, usability.

More standardization, how to start implementing.

Recasting DCT as evolving as opposed to novel - this will promote greater acceptance

would be valuable to have Sponsors, CROs, Vendors break out separately (i.e. all sponsors together, CROs together, etc.) and see what the various challenges and things working... then synthesize...

Further collaboration with various stakeholders to address everyone's perspective.

Closing poll: Reflecting on these challenges, what solutions or next steps are most important to consider?

Provide support for the early adopters - educational, regulatory, and even financial, where possible.

Harmonized guidance/approach from health authorities

Detail level DCT operational recommendations (which we know FDA guidance will not cover) to include the consideration for each solution and the common use cases

Building education pieces across the stakeholders

Early involvement from all stakeholder groups

Work with regulatory agencies to help sponsors feel more comfortable that DCT solutions should be considered/incorporated into trials.

Develop a glossary / definitions (if it has not already been done by CTTI or others) so everyone is speaking the same language

Developing educational materials about DCT that is targeted to different stakeholders.

Education - educating sites, patients - all stakeholders on what DCT means. that it is not all or nothing - meaning there is a hybrid component. outlining what the potential value is for the different stakeholders.